Fair Value Calculator Fair Value Calculator
EN DE

INDIAGLYCO (INDIAGLYCO) Fair Value & Analysis

Basic Materials · Market cap ₹72.1B

I INDIAGLYCO INDIAGLYCO · NSE
Price₹1,075
Fair Value₹645.96
Upside-39.9%
Quality43/100
Watch INDIAGLYCO for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹446.33 – ₹894.07

Fair value as of: Jul 3, 2026

From 16 valuation models · updated today

Share price +9.6% over the past month.

Price vs Fair Value (12 months)

₹1,150 ₹795.33 Fair Value ₹645.96 Jul 2025 Jul 2026

12‑month range ₹795.33 – ₹1,150 · fair‑value band ₹446.33 – ₹894.07 · the ₹1,075 price screens above the ₹645.96 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

INDIAGLYCO (INDIAGLYCO) currently trades at ₹1,075, while our model-based Fair Value estimate is ₹645.96 — implying the stock looks roughly 39.9% overvalued today. We read business quality at 43/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, INDIAGLYCO generated revenue of ₹42.1B at a net margin of 7.0%. Revenue grew 13.1% year over year. It earns a return on equity of 11.3%. Net debt stands at ₹16.4B. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹42.1B
Revenue growth (YoY) +13.1%
Net margin 7.0%
Return on equity 11.3%
Free cash flow −₹1.7B FY2026
P/E ratio 23.4
More key figures
Operating margin 12.8%
EPS (TTM) ₹45.97
EPS growth (YoY) +31.9%
Net debt ₹16.4B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

INDIAGLYCO reported revenue of ₹42.1B in FY2026 versus ₹28.7B in FY2022, a compound +10.1%/yr. Reported net income was ₹2.9B in FY2026, compounding −3.7%/yr from FY2022.

Revenue +10.1%/yr
FY22 ₹28.7B
FY23 ₹26.4B
FY24 ₹32.9B
FY25 ₹37.7B
FY26 ₹42.1B
Net income −3.7%/yr
FY22 ₹3.4B
FY23 ₹1.3B
FY24 ₹1.7B
FY25 ₹2.3B
FY26 ₹2.9B

Is INDIAGLYCO fairly valued? → Check now

Similar stocks

6 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN €443.00 €109.98 -75%
Shin-Etsu Chemical Co SHECY $22.62 $12.94 -43%
BASF SE BAS €49.17 €23.76 -52%
Ningxia Baofeng Energy Group 600989 ¥23.43 ¥34.39 +47%
Dow Inc D1OW34 R$43.92 R$86.14 +96%
Ganfeng Lithium Group 002460 ¥67.60 ¥22.08 -67%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is INDIAGLYCO (INDIAGLYCO) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹645.96 versus a price of ₹1,075 — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INDIAGLYCO?
Our model-based fair value for INDIAGLYCO is ₹645.96 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹1,075.
What is the quality score of INDIAGLYCO?
INDIAGLYCO has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of INDIAGLYCO (INDIAGLYCO)?
INDIAGLYCO reported trailing-twelve-month revenue of about ₹42.1B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of INDIAGLYCO?
The net profit margin of INDIAGLYCO is about 7.0%, meaning it keeps roughly 7.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.